Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Members of the DeLIVER consortium and their collaborators have tested the performance of hepatocellular carcinoma risk prediction models in patients with cirrhosis and cured hepatitis C infection.

The risk of liver cancer is increased in patients with cirrhosis and cured hepatitis C virus (HCV) infection. These patients are screened regularly with the aim of detecting any cancers that do develop as early as possible and improving patient outcomes. However, the risk of cancer varies substantially between these individuals. If an individual patient’s risk could be better predicted, clinicians may be able to target their surveillance resources to those who might benefit the most.

Several liver cancer risk prediction models have been developed already but their accuracy has not yet been fully tested. Dr Hamish Innes (Glasgow Caledonian University and a member of the DeLIVER early cancer detection consortium led by University of Oxford’s Professor Ellie Barnes) and colleagues assessed the relative performance of six risk prediction models in two external “validation” cohorts.

Using data from the Scotland HCV clinical database and the STOP-HCV study, the team found that the “aMAP” model performed best in terms of calibration and discriminating between patients who go on to develop liver cancer versus those who do not. They observed that discrimination of the models varied by cohort, age and HCV genotype (for genetic risk scores), and that some risk models underpredicted liver cancer risk. These results highlight the importance of this validation step and further research before models can be used to support clinical decision-making.

Read the full publication in JHEP Reports.

Similar stories

Funding to compare imaging modalities for liver cancer detection

The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.